Alon Ben-Noon is the CEO and co-founder of NeuroSense Therapeutics, a clinical stage drug development company offering ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases. Avraham Hermon sat down with Alon in the NeuroSense offices in Herzliya. They discussed the inspiration for creating a new ALS treatment, how to create results using a small team, raising money, dealing with investors, the mentality of a startup founder, the role of patents in biotech companies and much more. Do you have a great innovation? We'd love to hear from you. Contact us by going to jmbdavis.com/startup/contact. Learn more at jmbdavis.com and jmbdavis.com/startup. Also available at https://soundcloud.com/jmbdavis/jeff-gabbay-of-argaman-technologies. Listen to all of the episodes at https://jmbdavis.com/podcast.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.